The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
From medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact Areas
Explore stories, news, insights, and data across articles, videos, and podcasts.
view all content types
in Europe and #21 in the world for aerospace engineering
of the student body are women
in Israel and Europe for research on artificial intelligence
The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Explore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATSATS is a community of supporters, innovators, and champions of possibility united by one mission: transforming Israel and the world through science and discovery.
Learn MoreFor more than 100 years, the Technion has been Israel's technological engine and leading driver of innovation, technology, and entrepreneurship, transforming ideas into impact.
Learn More
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreFrom medicine to security, explore how the Technion is advancing Israel and improving lives around the world.
View All Impact AreasExplore stories, news, insights, and data across articles, videos, and podcasts.
view all content typesExplore ATS, the Technion, and the people behind the breakthroughs redefining what's possible for Israel and the world.
Learn More About ATS
Webinar with Professor Asya Rolls
Why is it that at least one-third of patients in medical trials get better with placebos? Many scientists are connecting the dots. Neuroscience has shown that every thought and emotion triggers specific brain activity that can be measured and manipulated.
In this special webinar, Technion Professor Asya Rolls talks about her research in understanding how one’s positive thoughts and expectations may impact the body’s ability to fight off germs. In one study, she showed that the release of the so-called “feel-good neurotransmitter” dopamine disabled tumor-promoting cells in the immune system of mice, allowing them to fight cancer.
Prof. Rolls is an associate professor in the Technion Rappaport Faculty of Medicine and an International Howard Hughes Medical Institute-Wellcome investigator. An expert in sleep deprivation and brain research, Prof. Rolls studies the physiological mechanisms by which emotions and thoughts affect physical health.

March 25, 2020
Join Professor Asya Rolls as she explores the link between emotions and stressful thoughts in healing and immune response.
1 min
X (opens in a new tab) / Facebook (opens in a new tab) / LinkedIn (opens in a new tab) / Email / Copy Link
Why do so many life-saving technologies never make it out of the lab? Prof. Marcelle Machluf demonstrates how combining scientific rigor with business vision is the only way to bring practical solutions to the patients who need them most. As a case in point, she shares her personal transformation from researcher to entrepreneur. This talk […]
Can the future of nutrition be more personalized, even down to our biology? A new study from the Technion suggests it can. Researchers in the Faculty of Biotechnology and Food Engineering recently discovered that men and women digest milk and plant-based milk alternatives differently — a breakthrough that could have far-reaching implications for nutrition science, […]
This op-ed is authored by Jenny Goldstein, chief development officer of the American Technion Society. For anyone who has faced a cancer diagnosis, or watched someone they love go through one, there is a particular anguish that comes with uncertainty. For me, that feeling is deeply personal. My father, an engineer whose love of science […]
Stay on top of the latest breaking scientific discoveries from Israel and the Technion. Subscribe to the ATS newsletter.